Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Immuno-Oncology (I-O) Focus

Explore the latest updates and expert interviews
Latest Videos Videos by Therapy Type Videos by Disease Videos by Congress Features Podcasts Expert Editorial Board

Welcome to the Immuno-Oncology (I-O) Focus

Explore the latest updates in this field by hematological disease and therapy type. I-O Focus showcases expert interviews and discussions, podcasts and e-learning.

I-O is at the frontier of hematological malignancy research, offering the potential for paradigm-changing new treatments. Agents including antibodies, immune checkpoint inhibitors, NK cells, vaccines and CAR T-cells are increasingly featured in treatment regimens, many of which are under testing in clinical trials currently. Although various questions remain open, it is essential that healthcare professionals understand these therapies, including recognizing and managing their toxicities, and when and how to use them.

Videos by Therapy Type

Antibodies
Checkpoint Inhibitors
CAR T-cell therapy
NK-cell therapy
Vaccines
1:24
Richter’s transformation in 2026: where does the field stand and what challenges remain?
Erin Parry • 17 Oct 2026
1:51
Insights into the current CLL treatment algorithm and emerging research directions
Matthew Davids • 17 Oct 2026
2:49
Efficacy and safety of GPRC5D-targeted QLS32015 in multiple myeloma
Jian Cui • 23 Sep 2026
1:28
Outpatient administration of T-cell-redirecting antibodies in multiple myeloma
Jeffrey Matous • 25 Sep 2026
View All Videos
2:18
Phase II atezolizumab shows durable responses in relapsed NK/T-cell lymphoma
Shinichi Makita • 30 Jun 2026
1:59
Optimizing diagnosis and treatment of NK/T-cell lymphoma
Shinichi Makita • 30 Jun 2026
2:18
Insights into the KEYFORM-008 trial: favezelimab plus pembrolizumab versus chemotherapy for HL
Guilherme Perini • 13 Jun 2026
1:37
The use of immunotherapies for the treatment of hematologic malignancies during pregnancy
Daan Dierickx • 2 Jun 2026
View All Videos
1:21
Is there a role for CAR T-cell therapy in the treatment pathway for CLL?
Marco Ruella • 16 Oct 2026
1:24
Richter’s transformation in 2026: where does the field stand and what challenges remain?
Erin Parry • 17 Oct 2026
1:51
Insights into the current CLL treatment algorithm and emerging research directions
Matthew Davids • 17 Oct 2026
1:17
Individualized bridging therapy before BCMA-directed CAR T-cell therapy
Jule Cecilia Artzenroth • 24 Sep 2026
View All Videos
10:42
SENTI-202: a first-in-class logic-gated off-the-shelf CAR NK-cell therapy for R/R AML
Stephen Strickland • 19 Sep 2026
14:46
Cellular therapy approaches in AML: novel targets, off-the-shelf CARs, & NK-cell therapy
David Sallmanet al. • 25 Apr 2026
9:06
Novel cellular therapy approaches in NHL: NK-cell therapies, allo and in vivo CARs, and more
Krish Patelet al. • 25 Apr 2026
1:21
Developing and testing a tandem CD19/ROR1 CAR-NK to overcome apoptotic resistance in CLL
Matthew Davids • 8 Dec 2025
View All Videos
3:37
Managing side effects associated with lymphoma immunotherapies: beyond CRS & ICANS
Joshua Brody • 29 May 2026
2:02
Impact of mRNA SARS-CoV-2 vaccination on CAR T-cell therapy outcomes in hematologic malignancies
Jowan Al-Nusair • 1 Jun 2026
2:21
Exploring vaccination strategies in MPNs: the current research landscape
Morten Orebo Holmström • 27 Apr 2026
2:51
Mitigating and managing key infections that patients are at risk of following CAR-T
Eleftheria Kampouri • 24 Mar 2026
View All Videos

Videos by Disease

Multiple Myeloma
CLL
Lymphoma
AML
ALL
MDS
1:24
Richter’s transformation in 2026: where does the field stand and what challenges remain?
Erin Parry • 17 Oct 2026
1:17
Individualized bridging therapy before BCMA-directed CAR T-cell therapy
Jule Cecilia Artzenroth • 24 Sep 2026
1:46
Hypogammaglobulinemia, infection risk, and IgG replacement therapy in myeloma
Wolfgang Willenbacher • 25 Sep 2026
2:49
Efficacy and safety of GPRC5D-targeted QLS32015 in multiple myeloma
Jian Cui • 23 Sep 2026
View All Videos
1:21
Is there a role for CAR T-cell therapy in the treatment pathway for CLL?
Marco Ruella • 16 Oct 2026
1:51
Insights into the current CLL treatment algorithm and emerging research directions
Matthew Davids • 17 Oct 2026
3:39
Understanding the CLL genome: current knowledge and remaining gaps
Anna Schuh • 16 Oct 2026
4:04
Addressing changes to genomic prognostic markers in CLL beyond the chemotherapy era
Anna Schuh • 16 Oct 2026
View All Videos
2:39
Genomic and immune signatures of ibrutinib response & resistance in Waldenström’s macroglobulinemia
Tina Bagratuni • 23 Sep 2026
1:26
Key advances in FL management expected to change practice over the next five years
Kim Linton • 11 Sep 2026
2:44
Changing community practice in FL: bispecific antibody delivery and treatment selection
Kim Linton • 11 Sep 2026
2:17
Community-based management of CAR-T and bispecific antibody-related CRS in B-cell lymphoma
Michael Jain • 11 Sep 2026
View All Videos
10:42
SENTI-202: a first-in-class logic-gated off-the-shelf CAR NK-cell therapy for R/R AML
Stephen Strickland • 19 Sep 2026
13:39
AVC-201: a CAR-T using a switchable module in AML
Marion Subklewe • 19 Sep 2026
4:14
Lessons from Phase I KITE-222: antigen escape, expansion, and the future of CAR-T in AML
David Sallman • 1 Oct 2026
17:01
Emerging immunotherapy strategies in AML: CAR-T, NK cells and T-cell engagers
David Sallmanet al. • 20 Sep 2026
View All Videos
1:20
New horizons in Ph+ ALL: the evolving role of bispecific antibodies
Josep-Maria Ribera • 14 Sep 2026
1:48
NGS-MRD assessment and targeted treatment selection in ALL
Josep-Maria Ribera • 14 Sep 2026
3:52
Avoiding common pitfalls when managing patients with ALL outside of specialist centers
Bijal Shah • 10 Sep 2026
3:32
The future of MRD-guided treatment in ALL: NGS and cell-free DNA approaches
Bijal Shah • 10 Sep 2026
View All Videos
4:28
Lessons from Phase III ENHANCE: TP53, transplant, and MRD in future HR-MDS combination trials
David Sallman • 1 Oct 2026
3:18
Targeted therapies and immunotherapy are redefining transplantation in AML
Arnon Nagler • 15 Jun 2026
2:25
Alterations in calreticulin and CD47 expression dynamics in myeloid malignancies
Ciro Rinaldi • 30 May 2026
1:58
Which strategies hold promise for treating TP53-mutated MDS?
David Sallman • 5 Dec 2025
View All Videos

Videos by congress

IMS 2026
EHA 2026
ASCO 2026
COMy 2026
iwCAR-T 2026
iwMyeloma 2026
1:46
Hypogammaglobulinemia, infection risk, and IgG replacement therapy in myeloma
Wolfgang Willenbacher • 25 Sep 2026
1:17
Individualized bridging therapy before BCMA-directed CAR T-cell therapy
Jule Cecilia Artzenroth • 24 Sep 2026
2:49
Efficacy and safety of GPRC5D-targeted QLS32015 in multiple myeloma
Jian Cui • 23 Sep 2026
1:35
Ramantamig safety and efficacy in relapsed/refractory multiple myeloma
Jeffrey Matous • 25 Sep 2026
View All Videos
2:18
Phase II atezolizumab shows durable responses in relapsed NK/T-cell lymphoma
Shinichi Makita • 30 Jun 2026
2:06
The evolving role of immunotherapy and frontline treatment strategies in DLBCL
Shinichi Makita • 30 Jun 2026
1:48
Insights from the AIEOP-BFM ALL trial: could blinatumomab replace high-dose chemotherapy in HR ALL?
Martin Schrappe • 11 Jun 2026
2:31
Emerging BTK inhibitor combination strategies being explored in CLL
Alexey Danilov • 13 Jun 2026
View All Videos
3:37
Managing side effects associated with lymphoma immunotherapies: beyond CRS & ICANS
Joshua Brody • 29 May 2026
4:14
How may purinostat methylate fit into the current treatment landscape for R/R MM and DLBCL?
Lijuan Chen • 30 May 2026
9:09
Mechanistic insights into purinostat mesylate for treating hematologic malignancies
Lijuan Chen • 30 May 2026
1:47
Pooled analysis data from EPCORE NHL-2: epcoritamab plus platinum salvage in R/R DLBCL
Yasmin Karimi • 1 Jun 2026
View All Videos
1:52
Bispecifics in myeloma: insights and challenges in a community setting
Heinz Ludwig • 14 May 2026
2:11
Genomic sequencing guides personalized treatment in multiple myeloma
Nikhil Munshi • 15 May 2026
2:44
Insights into the disease biology & role of T-cell redirecting therapies in EMD
Rakesh Popat • 15 May 2026
3:22
Expanding access to bispecific antibodies and CAR T-cell therapy in myeloma
Rakesh Popat • 15 May 2026
View All Videos
12:16
The future of T-cell engagers and CARs in acute lymphoblastic leukemia
Bijal Shahet al. • 25 Apr 2026
12:13
Updates on T-cell engagers and CARs in CLL: liso-cel, novel agents, and resistance mechanisms
Alexey Danilovet al. • 25 Apr 2026
14:46
Cellular therapy approaches in AML: novel targets, off-the-shelf CARs, & NK-cell therapy
David Sallmanet al. • 25 Apr 2026
25:30
Dual-targeting CARs in LBCL: trial updates and discussing the role of bridging therapy
Akil Merchantet al. • 26 Apr 2026
View All Videos
11:43
Immunotherapies in myeloma: novel bispecific data, off-the-shelf CAR-T, and trispecific approaches
Binod Dhakalet al. • 12 Apr 2026
13:27
Early use of immunotherapy in myeloma: TecDara, bispecific consolidation, and alpha emitter therapy
Damian Greenet al. • 12 Apr 2026
13:35
Expanding our understanding of the role of the tumor microenvironment in multiple myeloma
Gareth Morganet al. • 11 Apr 2026
12:53
Advances in myeloma genomics: characterizing structural variation and identifying prognostic factors
Brian Walkeret al. • 11 Apr 2026
View All Videos

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals